Fingolimod-associated PML in a patient with prior immunosuppression

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Neurology

• Publication date

  2016-05-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.0000000000002654PMID 27164718PMCID PMC4862251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

  2015cited by this paper
• Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate

  2015cited by this paper
• Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

  2014cited by this paper
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

  2012influential reference
• Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy

  2012cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper

• Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data

  2025cites this paper
• Performance of Ultrasensitive Polymerase Chain Reaction Testing for JC Polyomavirus in Cerebrospinal Fluid Compared with Pathological Diagnosis of Progressive Multifocal Leukoencephalopathy

  2024cites this paper
• Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis

  2023cites this paper
• Co-occurrence of glioma and multiple sclerosis: Prevailing theories and emerging therapies.

  2023cites this paper
• Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report

  2022cites this paper
• Leucoencefalopatía multifocal progresiva en la era de los nuevos tratamientos modificadores de la enfermedad para la esclerosis múltiple

  2021cites this paper
• Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis.

  2021cites this paper
• Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature

  2021cites this paper
• Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis

  2021cites this paper
• JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis

  2020cites this paper
• Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

  2020cites this paper
• What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature.

  2020cites this paper
• Adherence to Hypertension Medications and Lifestyle Recommendations among Underserved African American Middle-Aged and Older Adults

  2020cites this paper
• Fingolimod for the treatment of multiple sclerosis in French West Indies, a real-world study in patients from African ancestry.

  2019cites this paper
• Estudio de factores que permitan la estratificación del riesgo de leucoencefalopatía multifocal progresiva en pacientes con esclerosis múltiple candidatos a recibir tratamiento con Natalizumab

  2019cites this paper
• Cerebellar progressive multifocal leukoencephalopathy in a patient with a history of Crohn’s disease and acute myeloid leukemia

  2019cites this paper
• Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis

  2019cites this paper
• Treatment strategies in multiple sclerosis : current and future practice considerations

  2019cites this paper
• Three cases of non-carryover fingolimod-PML

  2019cites this paper
• Siponimod for the treatment of secondary progressive multiple sclerosis

  2018cites this paper
• Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.

  2018cites this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

  2018cites this paper
• Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration

  2018cites this paper
• Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.

  2018cites this paper
• Progressive multifocal leukoencephalopathy after fingolimod treatment

  2018cites this paper
• Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

  2018cites this paper
• Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway

  2018cites this paper
• Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing

  2018cites this paper
• MRT-Veränderungen bei Immunmodulation

  2018cites this paper
• An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma

  2018cites this paper
• The current long-term treatment of multiple sclerosis: the advantages and disadvantages of oral treatment

  2018cites this paper
• When and how disease‐modifying drugs for multiple sclerosis should be changed in daily practice

  2017cites this paper
• Endothelial cells and lymphatics at the interface between the immune and central nervous systems: implications for multiple sclerosis

  2017cites this paper
• Fingolimod-associated PML with mild IRIS in MS

  2017cites this paper
• Drug‐induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database

  2017cites this paper
• Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy

  2017cites this paper
• Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis

  2017cites this paper
• Neurological safety of fingolimod: An updated review

  2017cites this paper
• Update on disease-modifying therapies for multiple sclerosis

  2017cites this paper
• Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy

  2017cites this paper
• Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

  2017cites this paper
• Ventricular tachycardia after initiation of fingolimod

  2017cites this paper
• Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.

  2017cites this paper
• Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology

  2017cites this paper
• Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events

  2017cites this paper
• Drugs approved for the treatment of multiple sclerosis: review of their safety profile

  2017cites this paper
• Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis

  2016cites this paper
• Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

  2016cites this paper
• Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.

  2016cites this paper
• Interdisziplinäres Risikomanagement in der Therapie der multiplen Sklerose

  2016cites this paper
• Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals

  2016cites this paper
• Title Progressive multifocal leukoencephalopathy after fingolimod treatment

  year unknowncites this paper
• Progressive multifocal leukoencephalopathy after fi ngolimod treatment

  year unknowncites this paper